282 related articles for article (PubMed ID: 6699409)
41. Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes.
Eue I; Kumar R; Dong Z; Killion JJ; Fidler IJ
J Immunother; 1998 Sep; 21(5):340-51. PubMed ID: 9789196
[TBL] [Abstract][Full Text] [Related]
42. Comparative effect of muramyl dipeptide in vivo and in vitro on the tumoricidal activity of rat peritoneal macrophages.
Reisser D; Jeannin JF; Lagadec P; Martin F
J Biol Response Mod; 1985 Oct; 4(5):460-3. PubMed ID: 4078593
[TBL] [Abstract][Full Text] [Related]
43. Bacterial lipopolysaccharide, phorbol myristate acetate, and muramyl dipeptide stimulate the expression of a human monocyte surface antigen, Mo3e.
Todd RF; Alvarez PA; Brott DA; Liu DY
J Immunol; 1985 Dec; 135(6):3869-77. PubMed ID: 3934269
[TBL] [Abstract][Full Text] [Related]
44. In vitro synergic effect of interferon gamma combined with liposomes containing muramyl tripeptide on human monocyte cytotoxicity against fresh allogeneic and autologous tumor cells.
Galligioni E; Santarosa M; Favaro D; Spada A; Talamini R; Quaia M
Tumori; 1994 Oct; 80(5):385-91. PubMed ID: 7839471
[TBL] [Abstract][Full Text] [Related]
45. Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.
Sone S; Lopez-Berestein G; Fidler IJ
Cancer Immunol Immunother; 1986; 21(2):93-9. PubMed ID: 3081250
[TBL] [Abstract][Full Text] [Related]
46. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.
Fidler IJ; Barnes Z; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1982 Feb; 42(2):496-501. PubMed ID: 7055801
[TBL] [Abstract][Full Text] [Related]
47. Generation of tumoricidal effector cells by human C-reactive protein and muramyl tripeptide: a comparative study.
Gautam S; Deodhar S
J Biol Response Mod; 1989 Oct; 8(5):560-9. PubMed ID: 2795096
[TBL] [Abstract][Full Text] [Related]
48. Immunologic and toxicologic study of disaccharide tripeptide glycerol dipalmitoyl: a new lipophilic immunomodulator.
Vosika GJ; Cornelius DA; Bennek JA; Sadlik JR; Gilbert CW
Mol Biother; 1990 Mar; 2(1):50-6. PubMed ID: 2185794
[TBL] [Abstract][Full Text] [Related]
49. Muramyl dipeptide and mononuclear cell supernatant induce Langhans-type cells from human monocytes.
Mizuno K; Okamoto H; Horio T
J Leukoc Biol; 2001 Sep; 70(3):386-94. PubMed ID: 11527988
[TBL] [Abstract][Full Text] [Related]
50. Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma.
Fidler IJ; Jessup JM; Fogler WE; Staerkel R; Mazumder A
Cancer Res; 1986 Feb; 46(2):994-8. PubMed ID: 3000591
[TBL] [Abstract][Full Text] [Related]
51. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
[TBL] [Abstract][Full Text] [Related]
52. Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells.
Galligioni E; Quaia M; Spada A; Favaro D; Santarosa M; Talamini R; Monfardini S
Int J Cancer; 1993 Sep; 55(3):380-5. PubMed ID: 8375921
[TBL] [Abstract][Full Text] [Related]
53. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
Fidler IJ; Fan D; Ichinose Y
Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047
[TBL] [Abstract][Full Text] [Related]
54. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes.
Asano T; McIntyre BW; Bednarczyk JL; Wygant JN; Kleinerman ES
Oncol Res; 1995; 7(5):253-7. PubMed ID: 8534931
[TBL] [Abstract][Full Text] [Related]
55. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens.
Ullrich SE; Fidler IJ
J Leukoc Biol; 1992 Nov; 52(5):489-94. PubMed ID: 1431559
[TBL] [Abstract][Full Text] [Related]
56. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
Liebes L; Walsh CM; Chachoua A; Oratz R; Richards D; Hochster H; Peace D; Marino D; Alba S; Le Sher D
J Natl Cancer Inst; 1992 May; 84(9):694-9. PubMed ID: 1569602
[TBL] [Abstract][Full Text] [Related]
57. Activation of rat Kupffer cells to tumoricidal cells by the immunomodulator muramyl tripeptide-phosphatidylethanolamine incorporated into the novel drug carrier lactosylated low density lipoprotein.
van de Water B; van Berkel TJ; Kuiper J
Mol Pharmacol; 1994 May; 45(5):971-7. PubMed ID: 8190111
[TBL] [Abstract][Full Text] [Related]
58. [L-MTP-PE--a potential antineoplastic agent].
Dzierzbicka K; Gozdowska M; Kołodziejczyk AM
Postepy Hig Med Dosw; 1997; 51(2):227-36. PubMed ID: 9235567
[TBL] [Abstract][Full Text] [Related]
59. Secretion of interleukin-6 (IL-6) by human monocytes stimulated by muramyl dipeptide and tumour necrosis factor alpha.
Sancéau J; Falcoff R; Beranger F; Carter DB; Wietzerbin J
Immunology; 1990 Jan; 69(1):52-6. PubMed ID: 1690177
[TBL] [Abstract][Full Text] [Related]
60. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide.
Killion JJ; Brown DR; Wilson MR; Lloyd MM; Fidler IJ
Oncol Res; 1994; 6(8):357-64. PubMed ID: 7894085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
